HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $39
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $45 to $39.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $45 to $39.